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Introduction: Patients with transthyretin familial amyloid polyneuropathy were first 
described in geographically restricted areas, but progressively more and more patients 
were identified outside these disease foci, with genetic and clinical heterogeneity and 
variable age at onset. 
Aims: The main goal of this project is to characterize late-onset transthyretin familial 
amyloid polyneuropathy patients from the North and Center of Portugal, about clinical 
manifestations at the diagnosis, demographics and genetic data. 
Methods: A retrospective study was performed involving 111 patients with late-onset 
familial amyloid polyneuropathy, diagnosed from 2007 to 2016, at Unidade Corino de 
Andrade - Centro Hospitalar do Porto. Patients’ files were accessed and data concerning 
demographics, family history, diagnosis delay, clinical manifestations, neurological 
evaluation, cardiac examination indices and laboratory findings at diagnosis were 
collected. 
Results: Patients belong to 93 families (51 from the Center of Portugal, 41 from the 
North and 1 from Lisboa and Vale do Tejo), fifty-one (54.8%) of them with family history. 
The disease in these patients showed: a male preponderance (1.5:1, more evident in the 
group without family history – 3.7:1); a mean age at onset of 61.7 ± 8.4 years (higher in 
male patients - 63.1±7.9 vs 59.6±8.7 years, p=0.0034); sensory neuropathy in 95.5% 
and motor neuropathy in 45.9%; on neurological examination, 40.3% had sensory 
dissociation and 24.3% a modified Polyneuropathy Disability score≥3; dysautonomia 
was present in 90.1% of patients; myocardiopathy was more evident in male patients 
and heart failure was present in 15 patients; only female patients had signs of severe 
renal dysfunction.  
Discussion: This study confirmed some of the conclusions of Japanese authors, 
including the dispersed distribution of these late-onset cases, the male predominance, 
the description of previous cases in families and the severe myocardiopathy. However, 
unlike Japanese studies, these patients had evident dysautonomia and sensory 
dissociation. We also confirmed the severe renal dysfunction in female patients. 
 
Keywords: familial amyloid polyneuropathy, transthyretin, late-onset Portuguese 
patients, clinical variability  
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Introdução: A polineuropatia amiloidótica familiar foi inicialmente descrita em áreas 
geográficas restritas. Nos últimos anos, cada vez mais doentes, com maior 
heterogeneidade clínica, genética e variabilidade na idade de início, foram sendo 
identificados fora destes focos de doença. 
Objetivo: O principal objetivo deste projeto foi caracterizar os doentes com 
polineuropatia amiloidótica familiar de início tardio, do Norte e Centro de Portugal, 
quanto às manifestações clínicas ao diagnóstico e aos dados demográficos e genéticos.  
Doentes e métodos: Foi realizado um estudo retrospetivo com 111 doentes com 
polineuropatia amiloidótica familiar de início tardio, diagnosticados entre 2007 e 2016, 
na Unidade Corino de Andrade do Centro Hospitalar do Porto. Foram recolhidos dos 
registos clinicos os seguintes dados: idade, sexo, idade do diagnóstico, história familiar, 
dados registados em consultas médicas, exame neurológico, avaliação cardiovascular 
e resultados analíticos. 
Resultados: Os doentes pertenciam a 93 famílias (51 do Centro de Portugal, 41 do 
Norte e uma de Lisboa e Vale do Tejo), das quais 51 doentes (54.8%) tinham história 
familiar. Neste grupo de doentes de início tardio encontramos predomínio de homens 
(1.5:1, sendo maior no grupo sem história familiar 3.7:1); a média de idade de início de 
doença foi 61.7 ± 8.4 anos (sendo maior nos homens 63.1±7.9 vs 59.6±8.7 anos, 
p=0.034); neuropatia sensitiva em 95.5% e neuropatia motora em 45.9%; ao exame 
neurológico, 40.3% apresentaram dissociação sensitiva e 24.3% com modified 
Polyneuropathy Disability score≥3; disautonomia em 90.1%; miocardiopatia mais 
evidente nos homens; insuficiência cardíaca em 15 doentes; e sinais de disfunção renal 
grave apenas em mulheres. 
Discussão: Este estudo confirmou algumas das conclusões dos autores Japoneses 
relativas à doença de início tardio, incluindo a distribuição mais dispersa destes doentes, 
o predomínio de casos em homens, a presença de história familiar e de cardiomiopatia. 
No entanto, ao contrário dos estudos Japoneses, os doentes apresentam disautonomia 
e dissociação sensitiva. Confirmámos também a presença de disfunção renal grave 
apenas em mulheres.  
 
Palavras-chave: polineuropatia amiloidótica familiar, transtirretina, doentes 
Portugueses de início tardio, variabilidade clínica 
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Familial amyloid polyneuropathy (FAP) is an autosomal-dominant, adult-onset 
disorder, with phenotypic and genotypic heterogeneity. Transthyretin familial amyloid 
polyneuropathy (TTR-FAP) is associated with over 100 different mutations in the 
transthyretin (TTR) gene, including the most common mutation methionine-for-valine 
substitution at position 30 (Val30Met) (Andrade, 1952, Saraiva et al., 1984, Araki and 
Ando, 2010). These pathogenic mutations lead to protein misfolding with formation of 
amyloid fibrils and, ultimately, amyloid deposition in tissues (predominantly in the 
peripheral nervous system, somatic and autonomic, and the heart) (Figure 1) (Merlini 
and Bellotti, 2003, Hou et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with TTR-FAP were first described in geographically restricted areas of 
Sweden, Japan and Portugal (Andrade, 1952, Andersson, 1976, Ikeda et al., 1987), but 
progressively more and more patients were identified outside these disease foci, with 
genetic heterogeneity and variable age at onset (AO) (Parman et al., 2016). 
Amyloid fibrils Misfolded and 
aggregated 
Folded 
Monomers 
Free 
Tetramer 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amyloid fibrils in peripheral 
and autonomic nerve tissues 
 
Figure 1: Amyloid fibril formation in transthyretin familial amyloid polyneuropathy. The pathogenic 
mutations decrease the stability of transthyretin tetramers and increase their dissociation into monomers, 
which self-assemble in the extracellular space, leading to the formation of non-fibrillar soluble oligomers 
and protofibrils that assemble to create insoluble amyloid fibrils deposits in peripheral and autonomic nerve 
tissues in later stages of disease (Merlini and Bellotti, 2003, Hou et al., 2007). 
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In Portugal, Andrade’s first description presented a disease of young adults (Andrade, 
1952) but since then more and more late-onset cases were diagnosed, disclosing a wide 
variation in AO from 19 to 82 years of age (Sousa et al., 1995). Besides, several aged-
asymptomatic gene carriers, up to 95 years, were identified, suggesting a variable 
penetrance of the gene (Sousa et al., 1995).  
Classical TTR-FAP was characterized as a disease of young adults with a positive 
family history, originated from localized regions, the disease foci, presenting a severe 
progressing mixed neuropathy that shows early involvement of small nerve fibers 
(Coutinho, 1980). The presenting symptoms are commonly neuralgic pain, loss of 
temperature and pain sensation and autonomic manifestations, including erectile 
dysfunction, bladder paresis, gastroparesis, constipation, diarrhea, sweating 
abnormalities and postural hypotension (Figure 2) (Coutinho, 1980, Conceicao et al., 
2016). Untreated neuropathy progresses rapidly with motor problems and loss of 
postural sensation. Other manifestations are weight loss, cardiac arrhythmia, renal 
failure, proteinuria and vitreous opacities (Coutinho, 1980, Conceicao et al., 2016). The 
terminal manifestations of the disease are severe weakness, marked trophic changes, 
dysphagia, and urinary and fecal incontinence (Coutinho, 1980, Conceicao et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CNS manifestations 
 Progressive dementia 
 Seizures 
 Ataxia  
 Headache 
 Spastic paresis 
 Stroke-like episodes 
 
Cardiovascular manifestations 
 Conduction blocks 
 Cardiomyopathy 
 Arrhythmia 
 Orthostatic hypotension 
 
Renopathy 
 Proteinuria 
 Renal failure 
 
Ocular manifestations 
 Vitreous opacification 
 Glaucoma 
 Abnormal conjuntival 
vessels 
 Papillary abnormalities 
 
Carpal tunnel syndrome 
Sexual dysfunction 
 
Peripheral sensory-motor neuropathy 
 Axonal, fiber lenght-dependent, 
symmetric, and progressive in distal to 
proximal direction 
 
Gastrointestinal manifestations 
 Nausea and vomiting 
 Early satiety 
 Diarrhea 
 Severe constipation 
 Alternating episodes of 
diarrhea and constipation 
 Unintentional weight loss 
 Anorexia 
 
Vesical manifestations 
 Recurrent urinary 
tract infection 
 Urinary retention 
 Urinary incontinence 
 
 
Figure 2: Clinical features associated with transthyretin familial amyloid polyneuropathy (CNS: Central 
Nervous System) (Adapted from Conceicao et al., 2016). 
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In the last two decades Japanese authors called the attention to the differences 
between patients with early-AO (< 50 years of age) and late-AO (≥ 50 years of age). 
They stated that early and late-onset patients are two distinct groups. Early-onset 
patients are related to endemic foci where patients follow the typical description of the 
disease. In contrast, late-onset patients have a sporadic presentation due to low 
penetrance of the gene, come from non-endemic regions with no relation to disease foci 
and are characterized by relative preservation of unmyelinated nerve fibers and axonal 
sprouting. Consequently, these patients have impaired superficial and deep sensation, 
early distal motor loss and relatively mild autonomic symptoms associated with a severe 
cardiomyopathy (Sobue et al., 2003, Koike et al., 2004, Koike et al., 2011, Koike et al., 
2012). 
Genotype heterogeneity, geographical origin of patient, penetrance of the gene 
mutation and AO, contribute to the wide variation in clinical presentation of TTR-FAP 
(Ando et al., 1993, Adams et al., 2012a, Koike et al., 2012, Adams et al., 2014). This 
wide spectrum of phenotypes makes difficult to recognize an index case of TTR-FAP 
and accurate diagnosis is often delayed for years. Delay in diagnosis is most pronounced 
in regions where TTR-FAP is not common and when there is no positive family history 
because there is a lack of awareness among physicians of that region, leading to higher 
rates of misdiagnosis and poorer patient outcomes (Plante-Bordeneuve et al., 2007, 
Koike et al., 2011, Adams et al., 2012a, Dohrn et al., 2013). Given the limited window for 
treatment effectiveness and the fast and irreversible tissue damage, an early and 
accurate diagnosis is essential to enable effective therapeutic intervention in early 
disease stages and better prognosis (Coelho et al., 2013, Plante-Bordeneuve, 2014, 
Ericzon et al., 2015).  
The main goal of this project is to assess clinical and genetic features of late-AO TTR-
FAP patients from the North and Center of Portugal. For this purpose, all late-onset 
patients diagnosed from 2007 to 2016 at Unidade Corino de Andrade - Centro Hospitalar 
do Porto, were characterized about the geographic origin, family history and the 
presenting symptoms at the diagnosis (length-dependent sensory-motor 
polyneuropathy, autonomic dysfunction, cardiac manifestations, ocular symptoms and 
renal dysfunction). 
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Patients and Methods 
A retrospective study was performed involving 111 patients with late-AO FAP (108 
Val30Met and 3 Val28Met), diagnosed from 2007 to 2016, at Unidade Corino de Andrade 
- Centro Hospitalar do Porto. The inclusion criteria were 1) Patients with TTR-FAP 
mutations identified by deoxyribonucleic acid analysis of blood leukocytes; 2) symptom 
or sign unequivocally associated with TTR-FAP; 3) late-onset TTR-FAP (defined as 
clinical manifestations of TTR-FAP at ages over 50 years old) (Sequeiros and Saraiva, 
1987, Misu et al., 1999, Koike et al., 2002). 
Patients’ files were accessed and data concerning demographics, clinical 
manifestations and results of complementary exams at the moment of diagnosis were 
collected. Diagnosis delay, defined as the interval from the initial manifestations related 
to FAP to the diagnosis of the disease, was also evaluated. In addition, family history 
and geographical distribution were assessed.  
Patients were classified as symptomatic after a complete routine evaluation that 
included neurological clinical assessment by an experienced neurologist, 
electrocardiogram, echocardiogram, and blood tests (peripheral blood cell count, renal 
function tests, including urinary protein content, creatinine clearance and NT-proBNP). 
When visual symptoms were present, ophthalmologic examination was performed.  
The symptoms and signs at presentation were categorized as elucidated in Table I: 
neuropathic symptoms, including sensory (paresthesia, numbness or pain) and motor 
symptoms (distal weakness); autonomic dysfunction, which consists of digestive 
symptoms (diarrhea, constipation, gastroparesis, nausea and vomiting), genito-urinary 
symptoms (sexual dysfunction, urinary incontinence, urinary tract infections and voiding 
difficulty or retention), cardiac symptoms or signs (syncope, palpitations, dizziness and 
orthostatic hypotension, defined as a decrease in systolic blood pressure of 20 mmHg 
or a decrease in diastolic blood pressure of 10 mmHg within three minutes of standing 
compared with blood pressure from the sitting or supine position (Freeman, 2016)) and 
xerophthalmia; ocular abnormalities, including vitreous opacities and glaucoma; and 
important weight loss, defined as loss of more than 10 percent of usual body weight over 
6 to 12 months (Collins, 2003). 
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Signs and symptoms 
Neuropathic symptoms Sensory symptoms Paresthesia 
Numbness 
Pain 
Motor symptoms Distal weakness 
Autonomic dysfunction Digestive symptoms Diarrhea 
Constipation 
Gastroparesis 
Nausea 
Vomiting 
Genito-urinary manifestations Sexual dysfunction 
Urinary incontinence 
Urinary tract infection 
Voiding difficulty and retention 
Cardiac symptoms or signs Syncope 
Palpitations 
Dizziness 
Orthostatic hypotension 
Xerophthalmia 
Ocular abnormalities Vitreous opacities 
Glaucoma 
Important weight loss  
 
Neurological examination 
Neurological examination was performed. Sensory dissociation was defined by 
reduced superficial sensation (nociception) along with preserved vibratory sensation.  
The modified polyneuropathy disability score (mPND score) was calculated (Table II). 
Onset of the disease was defined by a neurologist specialized in the disease as the 
occurrence of the first progressive characteristic symptoms, coincident with an abnormal 
neurological observation or signs of other organ involvement.  
 
 
Table I: Signs and symptoms categories.  
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mPND Score Definition 
I Sensory disturbance but preserved walking capacity. 
II Impaired walking capacity but ability to walk without stick or 
crutches. 
IIIa Walking with help of one stick or crutch. 
IIIb Walking with help of 2 sticks or crutches. 
IV Confined to wheelchair or bedridden. 
 
Cardiac assessment 
Increased interventricular septum (IVS) thickness (>11 mm) was used as a marker 
suggestive of cardiac amyloid deposition (Olofsson et al., 2002, Koike et al., 2011). The 
IVS thickness was measured by two-dimensional and M-mode echocardiography.  
The presence of a decreased ejection fraction (≤40%) on echocardiography and an 
increased level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) were 
considered signs of cardiac failure (Koike et al., 2012, Ponikowski et al., 2016). NT-
proBNP levels was categorized as above the upper limit of individual normal level and 
≥900 pg/ml, a range with high positive predictive value for chronic heart failure in patients 
with ≥ 50 years (Januzzi et al., 2005). 
Finally, electrocardiographic studies were analyzed for rhythm and conduction 
disturbances, including atrial fibrillation, bradycardia, atrial-ventricular and bundle branch 
blocks. Patients with implanted pacemaker had no electrocardiographic study. 
 
Laboratory findings 
Results from proteinuria were divided in four groups: 0.030-0.300 g of proteinuria on 
a spot urine protein-to-creatinine ratio, considered as microalbuminuria; >3.500 g of 
proteinuria on a spot urine protein–to-creatinine ratio, defined as nephrotic-range; and 2 
intermediate groups (0.300-1.000 g and 1.000-3.500 g) (Lin and Denker, 2016). 
The creatinine clearance was divided in 5 groups according to Kidney Disease 
Outcomes Quality Initiative classification of chronic kidney disease (Table III). 
Levels of hemoglobin equal or lower than 12.0 g/dL were considered as anemia.  
Table II: Modified polyneuropathy disability score (mPND score) (Adams et al., 2015). 
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Stage 
Glomerular Filtration 
Rate (ml/min/1.73m2) 
Description 
1 ≥ 90 Normal or high kidney function. 
2 60-89 Mildly reduced kidney function. 
3 30-59 Moderately reduced kidney function. 
4 15-29 Severely reduced kidney function. 
5 < 15 or on dialysis 
Very severe decreased kidney function or 
end-stage kidney failure. 
 
Statistical analysis 
Patient characteristics are reported as numbers and percentages for categorical 
variables and medians, with interquartile range, or means ± standard deviation for 
continuous variables. The t-Student test for independent samples and Mann-Whitney 
test were conducted as appropriate. A p-value of <0.05 was considered statistically 
significant. Statistical software used was IBM SPSS Statistics24. 
This protocol was approved by the Comissão de Ética para a Saúde e Gabinete 
Coordenador de Investigação do Departamento de Ensino, Formação e Investigação do 
Centro Hospitalar do Porto. 
Table III: Classification of chronic kidney disease according to Kidney Disease Outcomes Quality Initiative 
(National Kidney, 2002). 
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Demographic and genetic features 
Between 2007 and 2016, 111 cases of FAP with late-onset (67 men and 44 women; 
male:female ratio of 1.5:1), belonging to 93 unrelated families, were referred to Unidade 
Corino de Andrade. From these 93 families, 51 (54.8%) had been ascertained previously 
and registered at the center or diagnosed elsewhere and the remaining 42 families had 
no description of a similar disease in previous generations.  
One hundred and eight patients (97.3%) had Val30Met variant of TTR and the 
remaining 3 patients had Val28Met variant of TTR. The mean AO was 61.7 ± 8.4 years, 
ranging from 50 to 80 years. Male patients had a mean AO significantly higher than 
female patients (63.1±7.9 vs 59.6±8.7 years, with p=0.034). For all patients mean 
diagnostic delay was 2.7±2.1 years, ranging from 0 to 10 years. The mean diagnostic 
delay was significantly higher in patients without family history as compared with patients 
with previous description of disease in their families (3.5±1.9 vs 2.3±2.1 years, p=0.003). 
We also analyzed the AO variability and gender ratio considering only one patient 
from each family. Patients with positive family history had statistically significant lower 
AO when compared with patients without family history (58.7 ± 7.9 vs 65.4± 8.1 years, 
p=0.001). In the group with family history, there were 27 male patients and 24 female 
patients (ratio 1.1:1). However, in the group with negative family history, there were 33 
male patients and only 9 female patients (ratio 3.7:1). 
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Geographic origin 
The families involved in this study were from different origins: 51 families from central 
areas, 41 from the North of Portugal and 1 from Lisboa and Vale do Tejo (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical characteristics at diagnosis 
Patients’ clinical characteristics at the diagnosis are elucidated in Table IV. The most 
frequent symptoms were paraesthesia and/or neuralgic pain in the distal portion of lower 
limbs in 106 patients (95.5%), followed by distal weakness which was present in 51 
patients (45.9%). Dysautonomia was detected in 100 patients (90.1%), with the majority 
of patients having digestive (70.3%) and cardiovascular (61.3%) symptoms. Glaucoma 
and/or vitreous opacities were seen in 6 patients (5.4%), and three of them had no 
neuropathic symptoms. Important weight loss was reported in 24 patients (21.6%).  
Figure 3: Distribution of families 
with late-onset cases of familial 
amyloid polyneuropathy in Portugal. 
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Neurological examination at diagnosis 
Complete and detailed sensory examination was available only for 72 patients. From 
these, sensory dissociation was present in 29 (40.3%) and severe loss of nociception 
and vibratory sensation was present in 36 (50.0%).  Seven (9.7%) patients had no 
sensory neuropathy. 
Polyneuropathy disability score (mPND score) was calculated: 6.3% of patients had 
no evidence of sensory or motor disturbances; 43.2% had only sensory disturbances; 
and, finally, for patients who had sensory and motor disturbances (50.5%), only 24.3% 
of the total required support for walking (Figure 4).   
  
 
 
 
 
 
 
 
 
Initial manifestations of TTR-FAP Late-onset FAP ATTR 
(n=111) (%) 
Neuropathic symptoms  107 (96.4) 
      Sensory symptoms 106 (95.5) 
      Motor symptoms 51 (45.9) 
Autonomic symptoms 100 (90.1) 
      Gastro-intestinal symptoms 78 (70.3) 
      Genito-urinary symptoms 54 (48.6) 
      Cardiovascular abnormalities 68 (61.3) 
      Xerophtalmia  15 (13.5) 
Ocular pathology (glaucoma or vitreous opacities) 6 (5.4) 
Important weight Loss 24 (21.6) 
Table IV: Initial clinical characteristics late-onset cases of transthyretin familial amyloid polyneuropathy. 
7
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Figure 4: Modified Polyneuropathy Disability Score of 111 late-
onset transthyretin familial amyloid polyneuropathy patients: 
mPND 0 – 6.3%; mPND 1 – 43.2%; mPND 2 – 26.1%; mPND 3a 
– 8.1%; mPND 3b – 3.6%; and mPND 4 – 12.6%. 
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Cardiac assessment 
Patients’ cardiac assessment is elucidated in Table V.  
Levels of NT-proBNP were elevated in 49 of 107 (45.8%) patients; of those, 29 (27.1% 
of all patients) had levels above 900 pg/ml, a range with high positive predictive value 
for chronic heart failure. A decreased ejection fraction, a sign of heart failure, was 
observed in 3 of 82 (3.7%) patients. However, at the time of diagnosis, symptoms and 
signs of heart failure were reported in only fifteen of these cases. 
On echocardiography, a thickened IVS was seen in 47 of 82 (57.3%) examined 
patients (Figure 5). The median of IVS thickness was 15.0 mm for male subjects and 
13.0 mm for female patients, a significant statistically difference (p=0.005). 
A pacemaker was implanted prior to the diagnosis of TTR-FAP in 9 patients (8.1%). 
Among the other 102 patients, the electrocardiographic study was performed in 98. 
Fourteen of the examined patients (14.3%) had sinus node dysfunction, 20 (20.4%) had 
atrioventricular conduction block and 39 (39.8%) had bundle branch block. In total 73 
patients out of 98 (74.5%) had conduction disturbances. 
 
Cardiac parameter assessed Number of 
patients (%) 
NT-proBNP (n=107) (relative and absolute frequencies)  
    > upper limit of normal 49 (45.8) 
    >900 pg/ml 29 (27.1) 
Echocardiogram (n=82) (relative and absolute frequencies)  
    Reduced Ejection Fraction  3 (3.7) 
    Increased IVS thickness  47 (57.3) 
        Male (n=30)(median [interquartile range])(mm)  15.0 [11.7,18.3] 
        Female (n=12)(median [interquartile range])(mm) 13.0 [11.9,14.1] 
Electrocardiographic study (n=98)  (relative and absolute 
frequencies) 
 
    Abnormal  73 (74.5) 
    Bradicardia/AF 14 (14.3) 
    Atrioventricular block 20 (20.4) 
    Bundle branch block 39 (39.8) 
Pacemaker at presentation 9 (8.1) 
Table V: Features on cardiac assessment of late-onset transthyretin familial amyloid polyneuropathy 
patients (IVS: interventricular septum). 
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Laboratory findings 
Patient laboratory findings at the time of diagnosis are summarized in Table VI.   
Normocytic and normochromic anemia was present in ten of 110 (9.0%) examined 
patients. The hemoglobin levels in these ten patients ranged from 9.0 g/dl to 11.7 g/dl. 
Urine protein content was evaluated in 103 patients. Sixty patients had normal results. 
Twenty one patients (20.4%) had only microalbuminuria with normal renal function. 
Twenty patients presented non nephrotic degrees of proteinuria. The two patients with a 
nephrotic-range proteinuria had also severely decreased renal function. These and three 
patients that were on dialysis at the moment of the diagnosis were female.  
 
 
 
 
 
 
 
 
 
 
 
p = 0.005 
Figure 5: Interventricular septum thickness in late-onset male 
and female TTR-FAP patients (p=0.005). 
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Laboratory parameter Number of patients (%) 
Hemoglobin (n=110)  
    Mean ± Standard Deviation (g/dl) 13.8±1.4 
    < 12 g/dl (relative and absolute frequencies) 10 (9.0) 
Creatinine Clearance (n=105) (relative and 
absolute frequencies) 
 
    ≥90 ml/min/1.73m2 28 (26.7) 
    60-89 ml/min/1.73m2 60 (57.1) 
    30-59 ml/min/1.73m2 15 (14.3) 
    15-29 ml/min/1.73m2 1 (1.0) 
    <15 ml/min/1.73m2 1 (1.0) 
Dialysis at presentation (n=111) 3 (2.7) 
Urine Protein Content  (n=103) (relative and 
absolute frequencies) 
 
    0.030 – 0.300 g 21 (20.4) 
    0.300 – 1.000 g 12 (11.7) 
    1.000 – 3.500 g 8 (7.8) 
    >3.500 g 2 (1.9) 
Table VI: Laboratory findings at diagnosis of late-onset transthyretin familial amyloid polyneuropathy 
patients. 
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We assessed the clinical features, and demographic and genetic data of all 
Portuguese patients with late-onset TTR-FAP, diagnosed in the last decade in the 
reference center of Porto. 
We aimed to compare late-onset Portuguese patients with previous descriptions of 
similar patients, namely the Japanese patients. In Japan, an important focus of early-
onset disease with the Val30Met mutation was described in 1968 with clinical 
characteristics very similar to those described by Andrade in Portuguese patients (Araki 
et al., 1968). Molecular diagnosis available since 1984 made possible the identification 
of an increasing genetic heterogeneity and phenotypic variability (Saraiva et al., 1984). 
In the last two decades Japanese authors highlight the differences between early and 
late-onset patients considering that these patients can be divided in two clearly distinct 
groups (Sobue et al., 2003, Koike et al., 2012). According to their observations, late-
onset patients originate from regions without any relation with the two well known 
endemic foci, in Nagano and Kumamoto districts, present very often as sporadic cases 
without previous family history, have a marked male predominance, show a neuropathy 
with early involvement of large nerve fibers, translated into the clinical presentation as a 
sensory and motor neuropathy without sensory dissociation and with minimal autonomic 
dysfunction and have also severe heart disease with infiltrative cardiomyopathy more 
than conduction disturbances (Araki et al., 1968, Sobue et al., 2003, Koike et al., 2012). 
As previously described (Coelho et al., 1994), this study confirms that many but not 
all late-onset patients originate from regions where the disease is not frequent, showing 
a more dispersed distribution with only few cases coming from the districts with higher 
concentration of cases, including Póvoa de Varzim, Esposende, Vila do Conde, Barcelos 
and  Figueira da Foz (Inês, 2015).  
Family history is present in 54.8% of patients. This result is similar to that reported in 
Italian, Japanese and Swedish late-onset TTR-FAP population, with 33%, 48% and 65% 
of cases having family history, respectively (Suhr et al., 2009, Koike et al., 2012, Luigetti 
et al., 2013).   
Male predominance is present, with a ratio male:female of 1.52:1 in the general 
sample. However if we only consider the group of sporadic probands the ratio is much 
higher (3.7:1). These results are similar to those described for late-onset patients from 
non-endemic regions, with this ratio varying from 4.36:1 to 6.14:1 (Sobue et al., 2003, 
Koike et al., 2012).  
The analysis of the distribution of the AO showed a significant difference between 
patients with and without family history. The AO of male and female patients was also 
significantly different, with women presenting an earlier AO. This result is somehow 
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surprising because in the general population of Portuguese patients the AO has always 
been described as significantly lower in male patients but may be due to the relative 
concentration of female patients in the group with a positive family history that also shows 
an early AO (Lemos et al., 2014).  
The majority of patients presented neuropathic symptoms, predominantly sensory 
disturbances (95.5%) while motor symptoms were less frequent, affecting 45.9% of 
examined patients. These results are similar to the experience in other countries with 
late-onset TTR-FAP, including Japan (Koike et al., 2012), Italy (Mariani et al., 2015), 
Sweden (Dohrn et al., 2013), France (Cappellari et al., 2011) and South of Portugal 
(Conceicao and De Carvalho, 2007). We identified sensory dissociation in 40.3% of the 
patients. However, many patients (50.0%) had a severe sensory loss that made 
impossible this differentiation and 9.7% had no sensory neuropathy. In general we may 
say that late-onset Portuguese patients do present sensory dissociation, a result 
strikingly different from French and Japanese series (Hornsten et al., 2010, Mariani et 
al., 2015).  
Similarly to results reported in France, Portuguese late-onset TTR-FAP cases had a 
median mPND score at diagnosis of 2, however only 24.3% of patients required aid for 
walking at the time of diagnosis (mPND score 3 or 4), a different result from that of French 
late-onset patients, who need walking aid in 39% of the cases (Adams et al., 2012b). 
The higher number of patients with previous family history and a shorter diagnostic delay 
may contribute to this difference.  
Autonomic dysfunction was present in the majority of patients (90.1%), a result that 
also distinguish these late-onset TTR-FAP patients from previous studies performed in 
Japan, Sweden, France, Germany and Italy, where the dysautonomia is less frequent, 
ranging from 10% in Japanese to 71% in Italian population (Cappellari et al., 2011, Koike 
et al., 2012, Dohrn et al., 2013, Mariani et al., 2015). 
Ocular amyloidosis was seen in 5.4% of these patients, similarly to other late-onset 
patients from Japan, where this manifestation is present in 2-10% of late-onset patients 
(Koike et al., 2002, Koike et al., 2012). Curiously 3 of these patients had no signs of other 
organ involvement, as previously reported (Ciulla et al., 1995, Seca et al., 2014). 
Amyloid deposition in the subendocardial layer of the myocardium, where the 
conduction system is located, explains the occurrence of cardiac conduction 
abnormalities and the frequent need for pacemaker implantation, frequently observed in 
early-onset patients. On the other hand, diffuse amyloid myocardial infiltration with 
ventricular wall thickening agrees with cardiac hypertrophy and subsequent heart failure 
in late-onset cases.  
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Electrocardiographic abnormalities were seen in 74.5% of the patients without 
pacemaker. The most common abnormality was bundle branch block, followed by 
atrioventricular block and sinus node dysfunction. A small group of patients (8.1%) 
needed pacemaker before diagnosis. A similar prevalence of conduction abnormalities 
was also verified in France and Sweden (Hornsten et al., 2010, Mariani et al., 2015). 
In more than a half of patients, the IVS thickness was increased.  In this analysis, 
male gender was clearly associated with more pronounced septal hypertrophy, similarly 
to findings reported for senile systemic amyloidosis and for late-onset TTR-FAP Swedish 
patients (Ng et al., 2005, Hornsten et al., 2010). This finding is in line with the hypothesis 
that female gender may confer some degree of protection against myocardial amyloid 
deposition (Rapezzi et al., 2008). The electrocardiographic and structural abnormalities 
were common in this population; however, ejection fraction was reduced in only 3 
patients. This latter result is consistent with cardiac failure, like the presence of NT-
proBNP>900 pg/ml. 
From those patients with reduced ejection fraction or NT-proBNP>900 pg/ml, only 15 
patients had a clinical condition consistent with cardiac failure, as described in the 
patients from South of Portugal (Conceicao and De Carvalho, 2007). This fact may be 
explained by their low level of physical activity associated with a mPND score≥2.  
Anemia was present in only 9.0%, a different result from a previous study conducted 
in Unidade Corino de Andrade, where 24.8% of patients had anemia (Beirao et al., 2004). 
This study suggested that anemia in TTR-FAP patients is caused by defective 
erythropoietin production (Beirao et al., 2004). The distinct results from these studies 
may be explained by the different disease duration of both samples: in the previous study 
the patients had an average disease duration of 6 years (Beirao et al., 2004), while in 
our study the observation was at the moment of diagnosis, which had a mean delay of 3 
years. 
Renal dysfunction and the degree of proteinuria are correlated with heavy amyloid 
deposition in the glomeruli, arterioles, and medium vessels (Lobato et al., 1998). A 
significant proportion of patients shows some degree of renal dysfunction, either 
proteinuria and/or reduction of glomerular filtration rate. The most severe involvement 
was observed only in female patients. Two patients had a nephrotic proteinuria with 
severe renal dysfunction and three patients were on dialysis. These results are in 
accordance with previous studies, that confer increased risk for nephropathy in patients 
>40 years old and in females (Lobato et al., 2004). As previously stated, 
microalbuminuria represents a first stage of clinical amyloid nephropathy (Lobato and 
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Rocha, 2012). The patient with mild proteinuria must therefore be followed in order to 
detect progression of renal disease. 
Diagnosis of TTR-FAP remains difficult and requires expertise and adequate 
diagnostic methods. The mean delay between the first symptoms and diagnosis is 2.7 
years, as described in Japanese (Koike et al., 2012), Italian (Verona) (Cappellari et al., 
2011), Swedish (Suhr et al., 2009) and French (Mariani et al., 2015) population but better 
than those from Germany, where the delay is about 6.1 years (Dohrn et al., 2013), and 
from Italian (Rome) experience, where the delay is 4.3 years (Luigetti et al., 2013). There 
are several reasons to explain this delayed diagnosis such as the absence of family 
history and the variable phenotypes (from isolated ocular manifestations to typical 
polyneuropathy). Late-AO, up to 80 years of age, is also associated with multiple co-
morbidities, making the diagnosis of this systemic disorder more difficult. The influence 
of having family history at the diagnostic delay is confirmed in this study: patients with 
family history had a delay of 2.3 years, while patients without family history had a delay 
of 3.5 years. This delay in diagnosis could be explained by the lack of awareness among 
patients without family history and among their physicians.  
 
This study has some limitations, namely its retrospective nature, the multiplicity of 
clinical evaluators and the absence of follow-up evaluations. Despite that, we were able 
to show some important characteristics of these patients confirming the similarities with 
other late-onset series but also some important differences. The cause of these 
contrasting clinical features may be partially related to genetic heterogeneity, but they 
are also present when we compare patients with the same Val30Met mutation. This 
suggests a partial influence of the ethnic background, through candidate genes that alter 
disease pathways and have a role as genetic modifiers (Santos et al., 2017).  
Further studies with a larger population and observation of disease progression as 
well as evaluation of the impact of different factors in the distribution of AO, along with a 
comparison between late- and early-onset TTR-FAP patients would help to better 
understand the natural history of this condition. 
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